Bio-Rad Laboratories | BIO - Current Liabilities


Bio-Rad Laboratories reported $917M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Agilent USD 2.27B 35M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Bio Techne USD 153.28M 12.85M Mar/2026
Bio-Rad Laboratories USD 917M 400M Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Danaher USD 7.46B 653M Mar/2026
General Electric Aerospace USD 40.03B 1.05B Mar/2026
Illumina USD 1.57B 19M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Laboratory Of America USD 2.64B 182.5M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Mettler Toledo International USD 1.11B 89.76M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
OraSure Technologies USD 44.08M 4.29M Mar/2026
Pacific Biosciences Of California USD 65.36M 7.48M Mar/2026
Quest Diagnostics USD 2.18B 101M Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Siemens EUR 49.52B 168M Mar/2026
Standard Biotools USD 42.2M 66.1M Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Tosoh JPY 354.52B 14.24B Mar/2026
Waters USD 1.24B 11.8M Dec/2025